ライフサイエンスコーパス: acute lymphocytic leukemia

1 ia, primary myelofibrosis, and T- and B-cell acute lymphocytic leukemia.

2 unctions as a tumor suppressor in pre-B cell acute lymphocytic leukemia.

3 is widely expressed in AML and some cases of acute lymphocytic leukemia.

4 -old female patient with relapsed pre-B-cell acute lymphocytic leukemia.

5 patients with acute myelogenous leukemia or acute lymphocytic leukemia.

6 ession of two LIM-only factors (LMOs) causes acute lymphocytic leukemia.

7 frequency of these translocations in T-cell acute lymphocytic leukemia.

8 for the prevention of central nervous system acute lymphocytic leukemia.

9 essentially absent in samples of chronic or acute lymphocytic leukemia.

10 ranscription factor involved in human T cell acute lymphocytic leukemia.

11 and pediatric acute myelogenous leukemia and acute lymphocytic leukemia.

12 the age-frequency distribution of childhood acute lymphocytic leukemia.

13 is proposed and applied to a recent trial in acute lymphocytic leukemia.

14 ounterbalances the activating role of T-cell acute lymphocytic leukemia 1 (TAL1).

15 tors [Gata binding protein 1 (Gata1), T cell acute lymphocytic leukemia 1 protein (Tal1), and Erythro

16 the principal hematopoietic regulator T-cell acute lymphocytic leukemia-1 (TAL1) is involved in regul

17 y elements across 200 kb of the mouse T-cell acute lymphocytic leukemia-1 (Tal1) locus, and, in addit

18 topoietic tumors, including 8 of 9 pediatric acute lymphocytic leukemia, 17 of 18 adult acute lymphoc

19 c acute lymphocytic leukemia, 17 of 18 adult acute lymphocytic leukemia, 21 of 23 adult acute myeloge

20 cute myelogenous leukemia (AML) (n = 39) and acute lymphocytic leukemia (ALL) (n = 11) patients who h

21 t was examined in 27 patients with untreated acute lymphocytic leukemia (ALL) and 31 patients with re

22 omal translocation in particular subtypes of acute lymphocytic leukemia (ALL) and acute myelogenous l

23 We report a case of a young woman with acute lymphocytic leukemia (ALL) and prolonged neutropen

24 ute myelo-genous leukemia (AML), rarely with acute lymphocytic leukemia (ALL) and with therapy relate

25 ladelphia chromosome-positive (Ph1-positive) acute lymphocytic leukemia (ALL) are 2 fatal BCR/ABL-dri

26 The MTHFR 677TT genotype was lower among 71 acute lymphocytic leukemia (ALL) cases compared with 114

27 as also observed with a p185BCR-ABL-positive acute lymphocytic leukemia (ALL) cell line generated fro

28 aEx3 but upregulated survivin-2B in EU-3, an acute lymphocytic leukemia (ALL) cell line with wild-typ

29 iety of acute myelogenous leukemia (AML) and acute lymphocytic leukemia (ALL) cell lines, cellular le

30 f either mTOR-containing complex is toxic to acute lymphocytic leukemia (ALL) cells and identify 2 pr

31 MLL-AF4 acute lymphocytic leukemia (ALL) has a poor prognosis.

32 ML) or Philadelphia chromosome (Ph)-positive acute lymphocytic leukemia (ALL) have achieved clinical

33 Acute lymphocytic leukemia (ALL) is the most prevalent p

34 nd beta1i is cytotoxic to primary cells from acute lymphocytic leukemia (ALL) patients.

35 The t(1;19) translocation of pre-B cell acute lymphocytic leukemia (ALL) produces E2a-Pbx1, a ch

36 ed complete remission, including 4 of 7 with acute lymphocytic leukemia (ALL), 2 of 4 with acute myel

37 orts a role for infection in the etiology of acute lymphocytic leukemia (ALL), and the involvement of

38 nical samples, including specimens of B-cell acute lymphocytic leukemia (ALL), mantle cell lymphoma,

39 transplant for acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), or chronic myeloid leu

40 rates p190(Bcr-Abl) which is mostly found in acute lymphocytic leukemia (ALL), whereas fusion of the

41 scription start site of p57KIP2 was found in acute lymphocytic leukemia (ALL)-derived cell lines.

42 myeloid leukemia (AML) and 25% of pediatric acute lymphocytic leukemia (ALL).

43 nic myeloid leukemia (CML) and some cases of acute lymphocytic leukemia (ALL).

44 on patterns are stable at time of relapse in acute lymphocytic leukemia (ALL).

45 improvement in the outcome of patients with acute lymphocytic leukemia (ALL).

46 blast phase) and 1 had Philadelphia-positive acute lymphocytic leukemia (ALL).

47 (HPRT)-reporter gene in children treated for acute lymphocytic leukemia (ALL).

48 hemotherapy regimens modeled after those for acute lymphocytic leukemia (ALL).

49 lapsed Philadelphia chromosome (Ph)-positive acute lymphocytic leukemia (ALL).

50 his mutant also caused a simultaneous B-cell acute lymphocytic leukemia (ALL).

51 ;21) chromosomal translocation inB-precursor acute lymphocytic leukemia (ALL).

52 98C were associated with lower risk of adult acute lymphocytic leukemia (ALL).

53 c and 50% of pre-B-cell receptor (preBCR(+)) acute lymphocytic leukemia (ALL).

54 myelogenous leukemia (AML, 42 patients) and acute lymphocytic leukemia (ALL, 18 patients).

55 ewly diagnosed non-Hodgkin's lymphoma (25%), acute lymphocytic leukemia (ALL; 53%), and chronic-phase

56 ukemia in blastic phase (CMLBP; n = 11), and acute lymphocytic leukemia (ALL; n = 12) received 40 mg/

57 c myelogenous leukemia (CML) and a cohort of acute lymphocytic leukemias (ALL).

58 ronic myelogenous leukemia [CML], and 1 with acute lymphocytic leukemia [ALL]), and the drug was well

59 , the most common translocation in pediatric acute lymphocytic leukemias, also disrupts CBFA2.

60 vival in human xenograft models of resistant acute lymphocytic leukemia and CLL when administered con

61 tigen receptors to treat relapsed/refractory acute lymphocytic leukemia and cytotoxic T-lymphocyte-as

62 kemia, and occurred very frequently in adult acute lymphocytic leukemia and pediatric acute myelogeno

63 healthy donors, acute myelogenous leukemias, acute lymphocytic leukemias, and myelodysplastic syndrom

64 itt's lymphoma, analysis of pediatric B-cell acute lymphocytic leukemia (B-ALL) samples showed increa

65 in polyglutamates of methotrexate (MTX) than acute lymphocytic leukemia blasts when incubated with th

66 tory potential of salinosporamide A in human acute lymphocytic leukemia CCRF-CEM cells, and its 10-fo

67 not block cell cycle progression in a T-cell acute lymphocytic leukemia cell line (CEM) sensitive to

68 f low cell density cultures of a human pre-B-acute lymphocytic leukemia cell line, SMS-SB: no other c

69 ay and the consequences of its inhibition in acute lymphocytic leukemia cells (ALL).

70 ld contribute to the commitment of childhood acute lymphocytic leukemia cells to proliferate and expl

71 protein fraction of mitochondria from human acute lymphocytic leukemia cells, which could be reconst

72 ity or resistance of glioblastoma and B-cell acute lymphocytic leukemia cells.

73 Inspection of rare pedigrees transmitting acute lymphocytic leukemia, chronic myelogenous leukemia

74 hat causes most chronic myelogenous and some acute lymphocytic leukemias (CML and ALL) in humans.

75 , RPMI-8392, established from a patient with acute lymphocytic leukemia, contain two major forms of c

76 kemia patients (20 acute myeloid leukemia, 1 acute lymphocytic leukemia) for the expression of BCRP m

77 A pre-B-cell acute lymphocytic leukemia miR, miR-143-3p, and a T-cell

78 Similar to acute lymphocytic leukemia, MM seems to include several

79 We used the Jurkat T cell acute lymphocytic leukemia model to characterize the rol

80 ses on patients with acute myeloid leukemia, acute lymphocytic leukemia, multiple myeloma, non-Hodgki

81 (n = 6), acute myeloid leukemia (n = 5), and acute lymphocytic leukemia (n = 5) exhibited low to medi

82 is especially effective in the treatment of acute lymphocytic leukemia, non-Hodgkin's lymphoma, and

83 ry B-cell malignancies or established B-cell acute lymphocytic leukemia or lymphomas.

84 leukemia and a small number of patients with acute lymphocytic leukemia or myelodysplastic syndrome.

85 gnancies (other than acute myeloid leukemia, acute lymphocytic leukemia, or myelodysplastic syndrome)

86 We performed a retrospective study on 105 acute lymphocytic leukemia patients treated with 12 Gy t

87 ETV6-RUNX1 carriers develop precursor B-cell acute lymphocytic leukemia (pB-ALL), the underlying gene

88 xpression of Stem cell leukemia (Scl)/T-cell acute lymphocytic leukemia protein 1 rescued hemogenic v

89 led minimal residual disease in hyperdiploid acute lymphocytic leukemia, providing "proof of concept.

90 MG-I mRNA and protein are increased in human acute lymphocytic leukemia samples.

91 demonstrated that most patients with T-cell acute lymphocytic leukemia (T-ALL) have activating mutat

92 rom healthy controls or patients with T cell acute lymphocytic leukemia (T-ALL), demonstrated reducti

93 re examined in 33 adult patients with T-cell acute lymphocytic leukemia (T-ALL).

94 ent in a variety of cancers including T-cell acute lymphocytic leukemia (T-ALL).

95 some cases of acute myelocytic leukemia and acute lymphocytic leukemia, the bcr-abl oncogene is invo

96 who had received chemotherapy for B-lineage acute lymphocytic leukemia were studied to determine whe